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The evolutionary process has conferred a dual – enzymatic and signaling – function on
the ancestral metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which has long
been known for converting the essential amino acid tryptophan (TRP) into neuroactive and
immunoactive catabolites (kynurenines). In addition to TRP catabolic activity, phosphory-
lated immunoreceptor tyrosine-based inhibitory motifs, present in the IDO1 protein, act
as docking sites for different molecular partners, which activate positive (transcriptional) or
negative (post-translational) modulation of IDO1 protein. The ligand-operated transcription
factor aryl hydrocarbon receptor (AhR) contributes to Ido1 transcription, and it can be oper-
ated by both exogenous and endogenous ligands, including L-kynurenine itself, the first
byproduct of TRP catabolism. Ligand-bound AhR is also a component of a ubiquitin ligase
complex responsible for regulatory proteolysis of different target proteins. Because IDO1
half-life is controlled by the ubiquitin–proteasome system, we here discuss the possibility
that AhR, in addition to enhancing Ido1 transcription, contributes to IDO1 regulation by a
non-genomic mechanism affecting the protein’s half-life.
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INTRODUCTION
Fine tuning of immune reactivity is guaranteed by the recruitment
of enzymes with disparate and pleiotropic functions. Indoleamine
2,3-dioxygenase 1 (IDO1) was first recognized as an immune regu-
lator in pregnancy (1), and subsequently, in numerous experimen-
tal and clinical settings, including autoimmune diseases, chronic
inflammation, transplantation, and neoplasia (2). IDO1 catalyzes
degradation of the essential amino acid tryptophan (TRP) along
a pathway that causes TRP starvation and yields several biologi-
cally active catabolites, collectively known as kynurenines. Similar
to other metabolic enzymes, IDO1 is endowed with a second
(“moonlighting”) function, which makes it a signal-transducing
molecule owing to the presence of two immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) (3, 4). When phosphorylated,
those motifs act as docking sites for distinct molecular part-
ners, which can either prolong IDO1’s half-life – thus sustaining
immunoregulatory effects – or shorten its half-life, so favoring
inflammatory responses (5).
The aryl hydrocarbon receptor (AhR), a ligand-activated tran-
scription factor that mediates dioxin toxicity (6), is of vital impor-
tance in the regulation of immune responses. Unbound AhR is
sequestered in the cytosol by the Hsp90/XAP2 chaperon complex
(7–10). Ligand binding to AhR induces conformational changes
that promote nuclear translocation of the receptor. In associa-
tion with the AhR nuclear translocator (Arnt), AhR modulates
the transcription of target genes through AhR-responsive ele-
ments (AHREs) (7, 8, 10). A wide array of distinct exogenous
and endogenous ligands bind AhR, including indole-containing
molecules and TRP metabolites such as l-kynurenine (l-kyn), the
upstream metabolite generated via TRP degradation (11, 12). The
immunoregulatory effects mediated by AhR have been known to
mostly involve its genomic activity, contributing to Ido1 transcrip-
tion (13). However, AhR is also involved in a non-genomic path-
way, being a component of an atypical ubiquitin ligase complex,
which regulates the proteasomal degradation of target proteins
(14–16).
REGULATORY PROTEOLYSIS OF IDO1 ENZYME
Intracellular proteins are continually “turning over” as they
become hydrolyzed to their constituent amino acids and replaced
by new synthesis, which absolves to several important homeostatic
functions. Cells contain multiple proteolytic systems to carry out
the degradation process and complex regulatory mechanisms, to
ensure that the continual proteolytic processes are highly selec-
tive. In all tissues, the ubiquitin–proteasome system presides over
the degradation of the majority of intracellular proteins (17).
In dendritic cells (DCs), under inflammatory conditions, IDO1
itself undergoes proteasomal degradation by associating with sup-
pressor of cytokine signaling 3 (SOCS3) through tyrosine phos-
phorylated ITIMs present in an IDO1 domain distinct from that
mediating its enzymatic function (3).
The crystal structure of the enzyme has indeed been solved
in its catalytically inactive conformation (18), unveiling the pres-
ence of two folding domains, namely, a large domain and a small
domain. The former contains the heme-binding site, forming the
catalytic cleft of the enzyme, while the latter contains two highly
conserved ITIMs, which, once tyrosine phosphorylated, can act
as docking sites for the association with different molecule part-
ners (5). Remarkably, the inspection of the crystal structure of the
enzyme (pdb code: 2D0T, 2D0U) shows that the phosphorylable
ITIM tyrosines are unexposed to the solvent, and thus,poorly com-
patible with the experimentally observed interaction with SOCS3.
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Multiple conformational states of enzymes have been reported
to play a role in molecular recognition, catalysis, and allosteric
modulation (19–21). Compliant to this paradigm, conformational
fluctuations of the large and small domains of IDO1 may exist and
be triggered by ligand binding and/or by post-translational mod-
ifications. Hence, the aforementioned tyrosine phosphorylation
of IDO1’s ITIMs may promote a specific conformational state of
IDO1, amenable the interaction with SOCS3.
Suppressor of cytokine signaling 3 represents the first IDO1
partner identified so far, capable of binding the ITIM docking sites
in the enzyme. As a member of the SOCS protein family, it acts as
a feedback inhibitor, blocking JAK/STAT signaling in response to
pro-inflammatory cytokines, such as IL-6. SOCS3 possesses a Src
homology 2 (SH2) domain, binding phosphotyrosine-containing
peptides, and a SOCS box, which recruits an E3 ubiquitin lig-
ase complex and targets several signaling proteins, disparate in
nature, for ubiquitination and proteasomal degradation (22, 23).
We have previously provided evidence that the SH2 domain in
SOCS3, by anchoring phosphorylated IDO1’s ITIMs, brings the
enzyme close to the E3 ubiquitin complex that ubiquitinates and
targets IDO1 for proteasomal degradation. This mechanism pro-
vides an explanation for the observed, inverse relationship between
SOCS3 and IDO1 expression in DCs. In fact, in DCs lacking
SOCS3, the immunoadjuvant effect of the immunogenic fusion
protein CD28-Ig is lost, and the latter behaves much like cyto-
toxic T lymphocyte-associated antigen 4 (CTLA4)-Ig, which is
immune suppressive in nature (24). This has been traced to CD28-
Ig’s unique ability to trigger IL-6 and SOCS3 activities, a property
unshared by CTLA4-Ig. IL-6-induced SOCS3 is indeed responsible
for degrading the protein product of Ido1, whose transcriptional
activation is mediated by IFN-γ (25). Mutations of the phospho-
rylable tyrosines in IDO1’s ITIM domains completely abolish the
ability of the enzyme to bind SOCS3, thus preventing its targeting
for proteasomal degradation (3, 26).
Therefore, the IDO1/SOCS3 association in DCs represents
a molecular mechanism whereby IDO1-positive (IDO1+) DCs,
expressing a tolerogenic phenotype, can turn into immunostimu-
latory antigen presenting cells (APCs), according to environmental
needs (3). According to the variety of pathophysiologic contexts
that DCs must face, proteasomal degradation of IDO1 could rep-
resent a non-genomic mechanism of modulation of the enzyme
in order to promptly turn IDO+ DCs into immunogenic IDO-
negative DCs under conditions in the local microenvironment that
require activation of the immune response. Regulatory proteolysis
of IDO1 by the ubiquitin–proteasome system may be a more com-
mon event than previously appreciated, and it may involve other
pathway besides that of IL-6-induced SOCS3 activation.
LIGAND-DEPENDENT E3 UBIQUITIN LIGASE ACTIVITY OF AhR
Although AhR has traditionally been defined as a transcrip-
tion factor involved in adaptive xenobiotic and in environmental
pollutant responses – including polycyclic and halogenated aro-
matic hydrocarbons, such as 2,3,7,8-tetrachorodibenzo-p-dioxin
(TCDD,“dioxin”) – the direct transcriptional activity of AhR alone
does not fully explain its toxicological and physiological effects.
Accumulating evidence suggests that AhR exhibits its regulatory
functions by “cross-talking” with a variety of signaling pathways,
including estrogen (ER) and androgen (AR) receptors (27, 28). In
addition to its genomic activity, AhR is also capable of mediating
non-genomic effects, by assembling an atypical E3 ubiquitin ligase
complex, CUL4BAhR that includes cullin 4B (CUL4B) (14, 28). E3
ubiquitin ligases act in the last step of a sequential reaction, also
involving E1 and E2 ligases, and culminating in the ubiquitination
of protein substrates.
Similar to the aforementioned ubiquitin ligase activity, medi-
ated by SOCS3 with IDO1 being the target protein, the ubiquitin
ligase activity of CUL4BAhR complex has been reported to target
several types of protein for proteolysis. Besides the transcriptional
regulation of ERs and ARs, ligand-operating AhR has recently
been shown to promote proteasomal degradation of the very
same receptors, by assembling the CUL4BAhR E3 ubiquitin ligase
complex (15). Similarly, ligand-based assembly of the CUL4BAhR
E3 ligase complex has been found to promote ubiquitination
of β-catenin (16), a transcription factor downstream from the
Wnt signaling pathway, leading to proteasomal degradation of β-
catenin in colon tumor cell lines. Interestingly, AhR-deficient mice
frequently develop colon tumor with abnormal accumulation of
β-catenin protein. Inversely, administration of AhR ligands effi-
ciently suppressed colon cancer in an established mouse model of
familial adenomatous polyposis. These findings suggest that AhR
ligands can be used to successfully prevent intestinal tumors, where
increased stabilization and accumulation of β-catenin may be
responsible for the initiation of intestinal carcinogenesis. Notably,
the substrates of CUL4BAhR ubiquitin ligase complex – ER, AR,
and β-catenin – all promote cellular proliferation in their target
tissues, suggesting that one putative biological role of the ubiqui-
tin ligase function of AhR could be the antiproliferative activity
through degradation of those transcription factors, promoting cell
proliferation. This raises the possibility of developing selective AhR
ligands in cancer therapy, by promoting ubiquitin ligase function.
Besides a direct role of AhR in assembling an ubiquitin ligase
complex, there is evidence that AhR may indirectly promote ubiq-
uitination of target proteins. One such recent mechanism has been
described for SOCS2-induced proteasomal degradation of tumor
necrosis factor receptor-associated factor (TRAF)6 in a model of
Toxoplasma gondii infection. In this study, both l-kyn and the
lipoxin LXA4 were found to induce SOCS2-dependent ubiquiti-
nation and proteasomal degradation of TRAF6, hindering pro-
inflammatory cytokine expression by DCs. In this case, the mech-
anism was mediated by the transcriptional activity of AhR, leading
to SOCS2 expression that, in turn, promoted TRAF6 polyubiquiti-
nation and proteasomal degradation of the adapter proteins (29).
Taken together, the results provide compelling evidence of a
prototypic indirect mechanism by which AhR, through AHRE
promoter-carrying genes (which include Socs2 and, interestingly,
Socs3) can mediate the proteasomal degradation of target pro-
teins. Notably, l-kyn is a TRP metabolite generated by IDO1 in
tolerogenic DCs (30), and it acts as endogenous ligand of AhR in
promoting IDO1 phosphorylation, leading to TGF-β production
(13). Moreover, the interaction of l-kyn with AhR can gener-
ate regulatory T cells (12). Overall, these observations shed light
on the crucial relationship between TRP metabolism and both
the genomic and non-genomic activities of AhR in modulating
immune responses.
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PERSPECTIVE ON AhR-MEDIATED, NON-GENOMIC
MODULATION OF IDO1
Several experimental models dissected the tight relationship
between TRP metabolism and the activity of AhR in modulat-
ing the immune response. It is well established that l-kyn, the
upstream metabolite generated by TRP-degrading enzymes, acts
as an endogenous AhR ligand, leading to generation of regulatory
T cells, and participating in immune homeostasis (12, 31). The
IDO1–AhR axis has been described in several settings of immune
tolerance, including maternal–fetal tolerance (32), immune sup-
pression induced by several human cancers (33), and endotoxin
tolerance (13). Therefore, the molecular dissection of the mech-
anisms that sustain the immunoregulatory IDO1–AhR axis has
become a compelling need.
As a transcription factor, AhR promotes IDO1 expression in
response to structurally disparate ligands such as l-kyn – in con-
ventional DCs in a model of endotoxin tolerance (13) – and TCDD,
during maturation of bone marrow-derived DCs (34), making
Ido1 as an AhR-responsive gene. Moreover, an autocrine signal-
ing loop involving IL-6, STAT3, and AhR was found to sustain
the constitutive expression of IDO1 in human cancer cells (33).
The genomic modulation of IDO1 by ligand-operating AhR also
involves non-canonical mechanisms mediated by kinase activity.
TCDD-activated AhR was independently reported to initiate a
rapid non-genomic signaling cascade, culminating in the activa-
tion of Src and Erk kinases (35–37). Recently, l-kyn–bound AhR
was found to promote IDO1 phosphorylation, through Src kinase-
mediated activity, which activates the signaling function of IDO1,
leading to the de novo synthesis of the enzyme via TGF-β pro-
duction (4, 13). Interestingly, in a model of murine vulvovaginal
candidiasis an increased expression of AhR was observed in the
vagina of both naïve and infected IDO1-deficient mice, suggesting
a further mechanism of mutual transcriptional regulation between
IDO1, the source of l-kyn, and its sensor AhR (38).
Besides its transcriptional activity, the non-genomic modality
of action of AhR could represent a further mechanism whereby
TRP metabolism and AhR cross their pathways. Analogous to
sex hormone receptors, regulated by AhR in both transcription-
ally and non-genomically fashions, IDO1 could represent another
substrate for the ubiquitin ligase activity of CUL4BAhR.
Proteasome-mediated degradation of IDO1 has been described
in DCs under IL-6-driven pro-inflammatory condition (3). The
ubiquitination of the enzyme is mediated by SOCS3 protein that
signals the enzyme to the proteasome. The mechanism is particu-
larly active in inflammatory DCs, where SOCS3 is highly expressed
and the cells are not required to manifest an immunoregulatory
phenotype. Regulatory proteolysis of IDO1 via the ubiquitin–
proteasome system may represent a non-genomic means of
switching off the enzyme. Similar to SOCS3, the CUL4BAhR com-
plex could promote the ubiquitination of IDO1, targeting it for
proteasomal degradation. Physiologically, the non-genomic mod-
ulation of IDO1 by ligand-bound AhR could be taken as a typical
negative feedback loop of enzyme regulation, where the same
trigger (liganded AhR) of its transcriptional expression can also
act as a quencher of the protein function, by promoting pro-
teasomal degradation. Such a mechanism would contribute to
a fine modulation of IDO1-based immunoregulatory response.
The hypothetical view of AhR-driven proteasomal degradation of
IDO1 is based on several observations that include the finding
that the enzyme is a proteasome substrate (3). Interestingly, both
IL-6 and SOCS3 (the trigger of the ubiquitination of IDO1) were
independently reported to be induced by activated AhR (33, 39).
In addition, SOCS2 – a member of the SOCS family in which
SOCS3 likewise belongs – is induced by l-kyn–activated AhR, and
it promotes the ubiquitination of the adapter protein TRAF6 (29).
Overall, these findings suggest that activated AhR, through its tran-
scriptional activity, is capable of inducing all of the components
(i.e., IL-6, SOCS3, and IDO1) of a putative feedback loop, promot-
ing intracellular conditions ensuring IDO1 ubiquitination and
proteasomal degradation. In addition, post-translational modi-
fications of substrates, such as phosphorylation, typically serve
for recruiting E3 ubiquitin ligases. In fact, tyrosine phosphory-
lation of the two ITIM motifs in the small domain of IDO1 is
needed for anchoring SOCS3 protein that bridges E3 ubiquitin
ligase (3). Interestingly, IDO1 phosphorylation may be promoted
by AhR activity in conventional DCs in a model of endotoxin
tolerance (13).
In this hypothetical scenario, AhR would play the canonical
role of transcription factor, capable of inducing the stimuli (IL-
6 and SOCS3) responsible for ubiquitination of IDO1 enzyme,
and would promote – through a non-canonical pathway – the
phosphorylation of IDO1 required for anchoring SOCS3. It is
also likely that the ubiquitin ligase activity ascribed to AhR might
directly act on IDO1 as a substrate, bypassing the “bridging” func-
tion mediated by SOCS3 (Figure 1). If so, the direct molecular
association of CUL4BAhR with IDO1 enzyme should be charac-
terized. All of the previously described complexes of CUL4BAhR
with both ER/AR and β-catenin are localized into the nucleus, as
involving the association of ligand-bound AhR with the specific
nuclear translocator Arnt. A major question relates to the subcel-
lular location where CUL4BAhR would bind the substrate IDO1.
There is no evidence of a nuclear localization of IDO1 enzyme or
of a cytosolic localization of CUL4BAhR. Thus, one should postu-
late that AhR assembles an ubiquitin ligase complex that involves
different molecular partners, not necessarily requiring the nuclear
translocation. In this regard, the C-terminus of Hsp70-interacting
protein (CHIP), a quality-controlling ubiquitin ligase, reportedly
promotes degradation of AhR. Since both CHIP and unliganded
AhR are mainly located in the cytosol, the degradation of AhR
through CHIP is likely to occur in the cytosol (40).
A second question relates to the nature of the AhR ligand that
could target IDO1 as a substrate for ubiquitination. In view of
a fine cross-talk between the TRP metabolism and AhR activity,
l-kyn and the downstream TRP metabolites could be good can-
didates for playing this role in a negative feedback loop, aimed at
controlling IDO1 enzymatic activity. As it holds true of ER/AR
signaling, in which AhR appears to modulate the receptors both
positively and negatively, although l-kyn has been shown to tran-
scriptionally induce IDO1 expression via AhR, later in an inflam-
matory context, the same molecules generated by IDO1 enzymatic
activity could also promote IDO1 ubiquitination and proteasomal
degradation.
Thus, l-kyn and its derivatives along the kynurenine pathway,
exploiting the genomic and non-genomic modality of action of
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FIGURE 1 | Aryl hydrocarbon receptor-mediated regulatory proteolysis
of IDO1. Ligand-operating aryl hydrocarbon receptor (AhR) promotes both
genomic and non-genomic activity. After nuclear translocation,
ligand-bound AhR dimerizes with the AhR nuclear translocator (Arnt) and
activates the transcription of target genes through AhR-responsive
elements (AHREs). Both IL-6 and SOCS3 are AhR-responsive genes and
may be independently induced by the genomic activity of AhR. In the
cytosol SOCS3, by anchoring tyrosine phosphorylated IDO1, brings the
enzyme close to the E3 ubiquitin complex (E3) that promotes the
polyubiquitination and the proteasomal degradation of IDO1. The
non-genomic activity of ligand-bound AhR promotes Src kinase-mediated
phosphorylation of IDO1, required for anchoring SOCS3. Ligand-bound AhR
can assemble an atypical E3 ubiquitin ligase complex, involving cullin 4B
(CUL4B), namely, CUL4BAhR. A direct association of CUL4BAhR with IDO1
protein has been prospected (inset) in determining the polyubiquitination
and the proteasomal degradation of IDO1.
the receptor AhR, could tightly control IDO1 activity in a sort of
negative feedback loop. By construing the ubiquitin ligase activity
of AhR as a sensor of environmental stress, as suggested in sex
hormone signaling (41), several inflammatory adverse effects of
dioxin-type ligands of AhR could be, at least in part, attributed
to the accelerated degradation of IDO1 that physiologically pre-
vents overreacting responses. In this regard, the appreciation of
exogenous/endogenous ligands that selectively activate the non-
genomic pathway of AhR might shed light on the biological role
of AhR-based modulation of IDO1.
The involvement of the atypical ubiquitin ligase activity of AhR
in the quenching of IDO1 activity may represent an attractive ther-
apeutic perspective. Translated into the clinic, the non-genomic
control of IDO1 by activated AhR becomes of great interest in neo-
plasia. The main strategy currently envisioned to tackle IDO1 clin-
ically is by inhibiting its enzymatic activity. The post-translational
modification of the enzyme,promoting its ubiquitination and pro-
teasomal degradation, could represent a valid alternative or a com-
plementary approach to the enzymatic inhibition. In this regard,
the purine analog, fludarabine, currently used as a chemother-
apeutic agent, has recently been proposed to act as a promoter
of proteasome-mediated degradation of IDO1 in tumors (42).
Noteworthy, the ubiquitin ligase function of AhR has also been
contextualized to the antiproliferative activity resulting from pro-
teasomal degradation of transcription factors (ER/AR, β-catenin)
that promote cell proliferation in target tissues. Although IDO1
does not possess a transcriptional activity of its own like other
substrates of CUL4BAhR, it is noteworthy that, in cancer tis-
sues, IDO1 plays a proliferative action (43–45), and therefore, the
putative CUL4BAhR-mediated degradation of IDO1 may result in
antiproliferative activity.
CONCLUSION
Dissecting the molecular mechanism of ubiquitin ligase activity of
AhR might lead to a better understanding of the diverse biological
effects induced by exogenous/endogenous AhR ligands. Specifi-
cally, clarifying this mechanism in relationship to the AhR–IDO1
axis might be of great interest in providing innovative IDO1-based
therapeutic targets. AhR-mediated non-genomic modulation of
IDO1 might provide druggable targets in cancer therapy, in alter-
native to or in combination with the already available enzyme
inhibitors. Thus, the identification of selective “non-toxic” AhR
ligands, activating the non-canonical pathway of the receptor,
represents an emerging area of research.
ACKNOWLEDGMENTS
We thank G. Andrielli for digital art and image editing. This
work was supported by the Italian Ministry of University and
Research (PRIN 2012S47X27 to Ciriana Orabona and Antonio
Macchiarulo), Bayer Grants Target Focus Grant no. 2012-03-0630
Frontiers in Immunology | Immunological Tolerance October 2014 | Volume 5 | Article 497 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pallotta et al. AhR-mediated, non-genomic modulation of IDO1 function
(to Francesca Fallarino and Davide Matino), Bayer Early Career
Investigator Award (to Davide Matino), and Bayer Special Project
Award (to Francesca Fallarino).
REFERENCES
1. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Pre-
vention of allogeneic fetal rejection by tryptophan catabolism. Science (1998)
281:1191–3. doi:10.1126/science.281.5380.1191
2. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling
and non-canonical NF-kappaB activation. Nat Rev Immunol (2007) 7:817–23.
doi:10.1038/nri2163
3. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3
drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and
antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008)
105:20828–33. doi:10.1073/pnas.0810278105
4. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al.
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by
dendritic cells. Nat Immunol (2011) 12:870–8. doi:10.1038/ni.2077
5. Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes:
a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol
Med (2012) 18:834–42. doi:10.2119/molmed.2012.00029
6. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspec-
tive on potential roles in the immune system. Immunology (2009) 127:299–311.
doi:10.1111/j.1365-2567.2009.03054.x
7. Poellinger L. Mechanistic aspects – the dioxin (aryl hydrocarbon) receptor. Food
Addit Contam (2000) 17:261–6. doi:10.1080/026520300283333
8. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol
Toxicol (1995) 35:307–40. doi:10.1146/annurev.pa.35.040195.001515
9. Matsumura F,Vogel CF. Evidence supporting the hypothesis that one of the main
functions of the aryl hydrocarbon receptor is mediation of cell stress responses.
Biol Chem (2006) 387:1189–94. doi:10.1515/BC.2006.146
10. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic
effects by TCDD. Biochim Biophys Acta (2003) 1619:263–8. doi:10.1016/S0304-
4165(02)00485-3
11. Dinatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM,
et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand
that synergistically induces interleukin-6 in the presence of inflammatory sig-
naling. Toxicol Sci (2010) 115:89–97. doi:10.1093/toxsci/kfq024
12. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA.
An interaction between kynurenine and the aryl hydrocarbon receptor can gen-
erate regulatory T cells. J Immunol (2010) 185:3190–8. doi:10.4049/jimmunol.
0903670
13. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl
hydrocarbon receptor control of a disease tolerance defence pathway. Nature
(2014) 511:184–90. doi:10.1038/nature13323
14. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, et al. Dioxin
receptor is a ligand-dependent E3 ubiquitin ligase. Nature (2007) 446:562–6.
doi:10.1038/nature05683
15. Ohtake F, Fujii-Kuriyama Y, Kato S. AhR acts as an E3 ubiquitin ligase to
modulate steroid receptor functions. Biochem Pharmacol (2009) 77:474–84.
doi:10.1016/j.bcp.2008.08.034
16. Kawajiri K, Kobayashi Y, Ohtake F, Ikuta T, Matsushima Y, Mimura J, et al.
Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+
mice with natural ligands. Proc Natl Acad Sci U S A (2009) 106:13481–6.
doi:10.1073/pnas.0902132106
17. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of
the proteasome block the degradation of most cell proteins and the genera-
tion of peptides presented on MHC class I molecules. Cell (1994) 78:761–71.
doi:10.1016/S0092-8674(94)90462-6
18. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of
human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation
by a heme-containing dioxygenase. Proc Natl Acad Sci U S A (2006) 103:2611–6.
doi:10.1073/pnas.0508996103
19. Cannon WR, Benkovic SJ. Solvation, reorganization energy, and biological catal-
ysis. J Biol Chem (1998) 273:26257–60. doi:10.1074/jbc.273.41.26257
20. Benkovic SJ, Hammes GG, Hammes-Schiffer S. Free-energy landscape of
enzyme catalysis. Biochemistry (2008) 47:3317–21. doi:10.1021/bi800049z
21. Bahar I, Chennubhotla C, Tobi D. Intrinsic dynamics of enzymes in the
unbound state and relation to allosteric regulation. Curr Opin Struct Biol (2007)
17:633–40. doi:10.1016/j.sbi.2007.09.011
22. Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, Burrows JF, et al. SOCS3 targets
Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses.
J Biol Chem (2007) 282:3418–22. doi:10.1074/jbc.C600216200
23. Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, et al.
CD33 responses are blocked by SOCS3 through accelerated proteasomal-
mediated turnover. Blood (2007) 109:1061–8. doi:10.1182/blood-2006-05-
023556
24. Orabona C, Belladonna M, Vacca C, Bianchi R, Fallarino F, Volpi C, et al. Cut-
ting edge: silencing suppressor of cytokine signaling 3 expression in dendritic
cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol (2005)
174:6582–6. doi:10.4049/jimmunol.174.11.6582
25. Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R,
et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and
CD86. Nat Immunol (2004) 5:1134–42. doi:10.1038/ni1124
26. Pallotta MT, Orabona C, Volpi C, Grohmann U, Puccetti P, Fallarino F. Pro-
teasomal degradation of indoleamine 2,3-dioxygenase in CD8 dendritic cells is
mediated by suppressor of cytokine signaling 3 (SOCS3). Int J Tryptophan Res
(2010) 3:91–7. doi:10.4137/IJTR.S3971
27. TianY. Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem
Pharmacol (2009) 77:670–80. doi:10.1016/j.bcp.2008.10.023
28. Ohtake F, Baba A, Fujii-Kuriyama Y, Kato S. Intrinsic AhR function underlies
cross-talk of dioxins with sex hormone signalings. Biochem Biophys Res Commun
(2008) 370:541–6. doi:10.1016/j.bbrc.2008.03.054
29. Mcberry C, Gonzalez RM, Shryock N, Dias A, Aliberti J. SOCS2-induced
proteasome-dependent TRAF6 degradation: a common anti-inflammatory
pathway for control of innate immune responses. PLoS One (2012) 7:e38384.
doi:10.1371/journal.pone.0038384
30. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much
ado about IDO. Trends Immunol (2003) 24:242–8. doi:10.1016/S1471-4906(03)
00072-3
31. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al.
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenic-
ity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010)
107:19961–6. doi:10.1073/pnas.1014465107
32. Hao K, Zhou Q, Chen W, Jia W, Zheng J, Kang J, et al. Possible role of the
‘IDO-AhR axis’ in maternal-foetal tolerance. Cell Biol Int (2013) 37:105–8.
doi:10.1002/cbin.10023
33. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter
M, et al. Constitutive IDO expression in human cancer is sustained by an
autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014)
5:1038–51.
34. Vogel CF, Wu D, Goth SR, Baek J, Lollies A, Domhardt R, et al. Aryl hydrocarbon
receptor signaling regulates NF-kappaB RelB activation during dendritic-cell
differentiation. Immunol Cell Biol (2013) 91:568–75. doi:10.1038/icb.2013.43
35. Dong B, Matsumura F. Roles of cytosolic phospholipase A2 and Src kinase in
the early action of 2,3,7,8-tetrachlorodibenzo-p-dioxin through a nongenomic
pathway in MCF10A cells. Mol Pharmacol (2008) 74:255–63. doi:10.1124/mol.
107.044669
36. Park S, Mazina O, Kitagawa A, Wong P, Matsumura F. TCDD causes suppres-
sion of growth and differentiation of MCF10A, human mammary epithelial
cells by interfering with their insulin receptor signaling through c-Src kinase
and ERK activation. J Biochem Mol Toxicol (2004) 18:322–31. doi:10.1002/jbt.
20040
37. Mazina O, Park S, Sano H, Wong P, Matsumura F. Studies on the mechanism
of rapid activation of protein tyrosine phosphorylation activities, particularly
c-Src kinase, by TCDD in MCF10A. J Biochem Mol Toxicol (2004) 18:313–21.
doi:10.1002/jbt.20041
38. De Luca A, Carvalho A, Cunha C, Iannitti RG, Pitzurra L, Giovannini G,
et al. IL-22 and IDO1 affect immunity and tolerance to murine and human
vaginal candidiasis. PLoS Pathog (2013) 9:e1003486. doi:10.1371/journal.ppat.
1003486
39. Brant F, Miranda AS, Esper L, Rodrigues DH, Kangussu LM, Bonaventura D,
et al. Immune response profile and development of pathology during Plasmod-
ium berghei Anka infection: the role of the aryl hydrocarbon receptor (AhR).
Infect Immun (2014) 82(8):3127–40. doi:10.1128/IAI.01733-14
www.frontiersin.org October 2014 | Volume 5 | Article 497 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pallotta et al. AhR-mediated, non-genomic modulation of IDO1 function
40. Morales JL, Perdew GH. Carboxyl terminus of hsc70-interacting protein (CHIP)
can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate
ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90)
in vitro. Biochemistry (2007) 46:610–21. doi:10.1021/bi062165b
41. Ohtake F, Fujii-Kuriyama Y, Kawajiri K, Kato S. Cross-talk of dioxin and estrogen
receptor signals through the ubiquitin system. J Steroid Biochem Mol Biol (2011)
127:102–7. doi:10.1016/j.jsbmb.2011.03.007
42. Hanafi LA, Gauchat D, Godin-Ethier J, Possamai D, Duvignaud JB, Leclerc D,
et al. Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via
a proteasome-mediated degradation mechanism. PLoS One (2014) 9:e99211.
doi:10.1371/journal.pone.0099211
43. Levina V, Su Y, Gorelik E. Immunological and nonimmunological effects
of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous
metastasis formation. Clin Dev Immunol (2012) 2012:173029. doi:10.1155/
2012/173029
44. Mei J, Li MQ, Ding D, Li DJ, Jin LP, Hu WG, et al. Indoleamine 2,3-dioxygenase-1
(IDO1) enhances survival and invasiveness of endometrial stromal cells via the
activation of JNK signaling pathway. Int J Clin Exp Pathol (2013) 6:431–44.
45. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, et al.
Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma
and drives the development of an immunosuppressant tumor microenviron-
ment. J Clin Endocrinol Metab (2014) 99:E832–40. doi:10.1210/jc.2013-3351
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest. The Review Editor Paolo Puccetti declares that,
despite being affiliated to the same institution as authors Maria Teresa Pallotta,
Francesca Fallarino, Davide Matino, Antonio Macchiarulo and Ciriana Orabona,
the review process was handled objectively.
Received: 18 July 2014; accepted: 24 September 2014; published online: 15 October
2014.
Citation: Pallotta MT, Fallarino F, Matino D, Macchiarulo A and Orabona C (2014)
AhR-mediated, non-genomic modulation of IDO1 function. Front. Immunol. 5:497.
doi: 10.3389/fimmu.2014.00497
This article was submitted to Immunological Tolerance, a section of the journal Frontiers
in Immunology.
Copyright © 2014 Pallotta, Fallarino, Matino, Macchiarulo and Orabona. This is
an open-access article distributed under the terms of the Creative Commons Attri-
bution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the origi-
nal publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | Immunological Tolerance October 2014 | Volume 5 | Article 497 | 6
